Cardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Conference Call February 29, 2024 4:30 PM ET

Company Participants

Laurence Watts - Investor Relations, Gilmartin Group

Mark Erlander - Chief Executive Officer

Fairooz Kabbinavar - Chief Medical Officer

Jamie Levine - Chief Financial Officer

Conference Call Participants

Mark Frahm - TD Cowen

Joseph Catanzaro - Piper Sandler

Andy Hsieh - William Blair

Operator

Welcome to the Cardiff Oncology Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference call over to Laurence Watts, Gilmartin Group. Please go ahead.

Laurence Watts

Thank you, Operator. Joining us on the call today from Cardiff Oncology are Chief Executive Officer, Mark Erlander; Chief Medical Officer, Dr. Fairooz Kabbinavar; and Chief Financial Officer, Jamie Levine.

During this conference call, management will make forward-looking statements including, without limitations, statements related to guidance, results, and the timing of the data readouts for onvansertib clinical trials. These forward-looking statements are based on the Company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to be different from these statements include factors the Company describes in the section entitled Risk Factors in our annual report on Form 10-K for the year ended December 31, 2023, filed with the SEC earlier today. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations.

Slides for today's investor call can be found on the homepage and the Events and Presentations tab on the Cardiff Oncology Web site at www.cardiffoncology.com.

With that, I will turn the call over to Chief Executive Officer, Mark Erlander. Mark?

Mark Erlander

Thank you, Laurence. Good afternoon, everyone, and thank you for joining the call. We have some very important new clinical data to share on the call today while we -- which we think is highly relevant to our current first-line metastatic colorectal cancer program. As you may be aware, last year, we made a highly consequential decision to shift our mCRC program from the second-line to the first-line setting. There were three factors that drove our decision. The first was the clinical signal from our second-line mCRC trial. The second was the new mechanism of action we discovered for onvansertib. And the third was the strong support from the FDA for the first-line clinical development plan.